PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
7579504-1	1995	In pre-clinical and limited clinical studies, high doses ( > or = 200 mg/day) of the triphenylethylene derivative toremifene showed activity in estrogen receptor (ER) negative and ER-unknown metastatic breast cancer after progression on tamoxifen, and a mechanism of action independent of hormone receptor binding was speculated.	Toremifene	117-127	nuclear receptor subfamily 4 group A member 1	Homo sapiens	292-308	
20209619-13	2010	Treatment of HR-positive patients with either tamoxifen or toremifene is appropriate.	Toremifene	59-69	nuclear receptor subfamily 4 group A member 1	Homo sapiens	13-15	
23904760-2	2013	The present retrospective study compared the efficacy and safety of toremifene and tamoxifen in the treatment of operable hormone receptor-positive breast cancer in premenopausal women.	Toremifene	68-78	nuclear receptor subfamily 4 group A member 1	Homo sapiens	122-138	
23904760-13	2013	CONCLUSIONS: In this retrospective study, the efficacy and safety profiles of toremifene and tamoxifen for the treatment of operable hormone receptor-positive breast cancer in premenopausal women were similar.	Toremifene	78-88	nuclear receptor subfamily 4 group A member 1	Homo sapiens	133-149	
7579504-2	1995	The CALGB conducted a Phase II trial (CALGB 8945) to test the efficacy of high dose toremifene in a population of patients who had hormone receptor-negative, metastatic breast cancer with limited prior chemotherapy exposure, good performance status, and measurable disease.	Toremifene	84-94	nuclear receptor subfamily 4 group A member 1	Homo sapiens	131-147